A new report conducted by doctors at the University of California-San Francisco claims that pharmaceutical companies are still not being transparent in the reporting of their clinical trials, finding that some are up to five times more likely to report positive findings than negative. PhRMA's Ken Johnson counters that drug companies are following reporting regulations more strictly than ever, as witnessed by the National Institutes of Health's clinical trials registry.
The full report is available through the Public Library of Science (PLoS).
--PWT
